leadf
logo-loader
viewOrthocell Ltd

Orthocell completes CelGro study accelerating dental implant treatments

The positive data comes as Orthocell is active in partnering discussions and will support the company to gain traction in key markets.

1561012625_1561009788_1-Imperial-Innovations-(2).jpg
CelGro continues to gain traction in Europe with strategic partnering activities ongoing

Orthocell Ltd (ASX:OCC) has completed the CelGro® single-stage dental implant study designed to assess effectiveness and predictability in accelerating treatment timeframes.

The marketing study follows the successful two-stage dental implant trial and market authorisation of CelGro in the European Union for dental bone and soft tissue applications.

Study results further validate CelGro as a superior medical device for bone and soft tissue repair and will assist in driving market adoption.

“CelGro as the best in class collagen membrane”

Orthocell’s managing director Paul Anderson said: “CelGro’s ability to deliver superior bone growth has the potential to revolutionise dental implant techniques and is highly desired by physicians and potential partners.

“The latest results provide further evidence that positions CelGro as the best in class collagen membrane.”

The 10 patients treated in the marketing study had previously suffered, in some cases for many years, from damaged, missing or diseased teeth.

Symptoms prior to treatment included severe irritation, bleeding gums, an inability to chew or eat certain foods and enjoy a normal diet.

Treatment completion in four months

After surgery with CelGro the impact on patients’ lives was ‘significant’ with patients having successfully generated enough new bone to stabilise their implants and complete treatment in about four months.

This is almost half the time of the usual two-stage dental implant treatment.

The performance study underpins the compatibility and versality of CelGro as a platform technology and highlights the potential to extend the company’s innovative dental product range.

Orthocell is also leveraging the EU regulatory approval and finalising its submission for US regulatory clearance.

 

Quick facts: Orthocell Ltd

Price: 0.425 AUD

ASX:OCC
Market: ASX
Market Cap: $78.53 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Orthocell Ltd named herein, including the promotion by the Company of Orthocell Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Orthocell's Paul Anderson hails 'fantastic outcome' in CelGro nerve repair study

Orthocell Ltd's (ASX:OCC) Paul Anderson speaks to Proactive's Andrew Scott soon after announcing positive long-term clinical data for its CelGro® nerve repair study. The regenerative medicine company has decided that the clinical results have met the study objectives and has now closed...

5 days, 14 hours ago

2 min read